RTW Investments, an investment firm, led a $181m Series D funding round in Nuance Pharma, a biopharmaceutical company. The round was also joined by GT Fund, CBC Group, Matrix Partners China, HBM Healthcare Investments and Konruns Pharmaceutical. "This is an important milestone for Nuance Pharma, which reinforces our deep industry expertise and strategic business model. We are well-positioned to advance the clinical development of our robust therapeutics pipeline, and we look forward to bringing in more assets to China and building a leading presence in these key therapeutic areas," Mark Lotter, Nuance Founder and CEO.